Stroke-induced Myocardial Dysfunction: Role of GDF-15 (SMOG-15) Clinical Work Package

The aim of this study is to analyze the relationship between the blood biomarker GDF-15 and heart damage after stroke.It is being conducted in France, in the Neurology Department of the Dijon University Hospital (Burgundy). The research is interventional because a biological blood test will be performed, as well as a heart rhythm recording and several cardiac echograms during the hospitalization of the participants and during the follow-up consultation scheduled 4 to 6 months after the stroke.A total of 130 stroke patients will participate in this study.Participation includes 4 visits:Inclusion visit (within 24 hours of the first stroke symptoms)visit 1 (within 24 to 72 hours of stroke)visit 2 (within 48 hours of visit 1)Visit 3 (approximately 4-6 months post-stroke)

Inclusion Criteria:Adult with acute symptomatic cerebral infarction documented by brain imaging on admission (cerebral angioscan or cerebral MRI)Whose first symptoms appeared within 24 hours before inclusionWhose consent to participate in this study was obtained from the patient or a close relative.Exclusion Criteria:Person with a history of symptomatic stroke, either ischemic or hemorrhagicAnyone with a history of heart disease including: atrial fibrillation or flutter (known or discovered on admission), chronic heart failure, pacemaker, defibrillator, or other cardiac devicesPerson with acute heart failure, suspected infective endocarditis, STEMI, or concurrent pulmonary embolismA person who is not a member or beneficiary of a social security systemPerson deprived of libertyPerson subject to a legal protection measure (curatorship, guardianship)Person subject to a legal protection measurePregnant, parturient or breastfeeding woman